The use of the R6 transgenic mouse models of Huntington' s disease in attempts to develop novel therapeutic strategies

被引：163
作者：
Li J.Y. [1 ]
Popovic N. [1 ]
Brundin P. [1 ]
机构：
[1] Neuronal Survival Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science
来源：
NeuroRX | 2005年 / 2卷 / 3期
关键词：
Huntington's disease; Neurodegenerative diseases; R6/2; Therapy; Transgenic mice;
D O I：
10.1602/neurorx.2.3.447
中图分类号：
学科分类号：
摘要：
Huntington's disease (HD) is a genetic neurodegenerative disorder. Since identification of the disease-causing gene in 1993, a number of genetically modified animal models of HD have been generated. The first transgenic mouse models, R6/1 and R6/2 lines, were established 8 years ago. The R6/2 mice have been the best characterized and the most widely used model to study pathogenesis of HD and therapeutic interventions. In the present review, we especially focus on the characteristics of R6 transgenic mouse models and, in greater detail, describe the different therapeutic strategies that have been tested in these mice. We also, at the end, critically assess the relevance of the HD mouse models compared with the human disease and discuss how they can be best used in the future. © The American Society for Experimental NeuroTherapeutics, Inc.
引用
收藏
页码：447 / 464
页数：17
相关论文
共 155 条
[1]  
Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Et al., Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice, Cell, 87, pp. 493-506, (1996)
[2]  
Menalled L.B., Chesselet M.F., Mouse models of Huntington's disease, Trends Pharmacol Sci, 23, pp. 32-39, (2002)
[3]  
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes, Cell, 72, pp. 971-983, (1993)
[4]  
Vonsattel J.P., DiFiglia M., Huntington disease, J Neuropathol Exp Neurol, 57, pp. 369-384, (1998)
[5]  
Kremer H.P., Roos R.A., Dingjan G.M., Bots G.T., Bruyn G.W., Hofman M.A., The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease, Neurosci Lett, 132, pp. 101-104, (1991)
[6]  
Kremer H.P., Roos R.A., Dingjan G., Marani E., Bots G.T., Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease, J Neuropathol Exp Neurol, 49, pp. 371-382, (1990)
[7]  
Qin Z.H., Wang Y., Sapp E., Cuiffo B., Wanker E., Hayden M.R., Et al., Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction, J Neurosci, 24, pp. 269-281, (2004)
[8]  
Landles C., Bates G.P., Huntingtin and the molecular pathogenesis of Huntington's disease, EMBO Rep, 5, pp. 958-963, (2004)
[9]  
Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S., Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death, Nature, 431, pp. 805-810, (2004)
[10]  
Saudou F., Finkbeiner S., Devys D., Greenberg M.E., Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions, Cell, 95, pp. 55-66, (1998)
12345678910